Drug Profile
Research programme: microRNA therapeutics - AstraZeneca/Regulus Therapeutics
Alternative Names: anti-microRNA-103/107; anti-microRNA-19; anti-microRNA-33a; anti-microRNA-33b; anti-miR-103/107; anti-miR-19; anti-miR-33a; anti-miR-33b; microRNA-103/107 therapeutics; microRNA-19 therapeutics; microRNA-33 therapeuticsLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; Regulus Therapeutics
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Cancer; Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA